Skip to main content
Clinical Trials/NCT05155163
NCT05155163
Active, not recruiting
Not Applicable

Stepped Care for Patients to Optimize Whole Recovery

Yale University3 sites in 1 country204 target enrollmentJune 28, 2023

Overview

Phase
Not Applicable
Intervention
Treatment as Usual
Conditions
Opioid Use Disorder
Sponsor
Yale University
Enrollment
204
Locations
3
Primary Endpoint
Change in pain interference using The Pain, Enjoyment of Life and General Activity (PEG) Scale
Status
Active, not recruiting
Last Updated
5 days ago

Overview

Brief Summary

This is a prospective, randomized clinical trial of 204 patients with opioid use disorder (OUD) and chronic pain (CP) to test the effectiveness of treatment as usual compared with Stepped Care for Patients to Optimize Whole Recovery (SC-POWR) to reduce pain interference (Aim 1) and decrease illicit opioid use, alcohol use, anxiety, depression, and stress, and improve sleep (Aim 2). Eligible participants will begin medications for opioid use disorder (MOUD) and will be randomized to receive SC-POWR (i.e., cognitive behavioral therapy (CBT), MOUD, and onsite groups for exercise [Wii Fit, Tai Chi] and stress reduction [relaxation training, auricular acupuncture] for 24 weeks. Participants will be followed for another 24 weeks to evaluate durability of treatment response on pain interference illicit opioid use, alcohol use, anxiety, depression, stress, sleep, and retention in MOUD (Aim 3).

Detailed Description

Participants who meet criteria for CP and OUD (N=204) will be initiated onto MOUD and randomized to 24 weeks of either treatment as usual (TAU) or 24 weeks of SC-POWR. SC-POWR patients will be "stepped up" according to a priori criteria. Patients randomized to SC-POWR will receive a behavioral intervention consisting of 12 Cognitive Behavioral Therapy (CBT) sessions over a 24-week period involving improvements in substance use and pain since baseline. Following 24 weeks of SC-POWR, patients are offered once monthly peer-support groups. This study receives support from and included in the HEAL Initiative (https://heal.nih.gov/).

Registry
clinicaltrials.gov
Start Date
June 28, 2023
End Date
August 31, 2026
Last Updated
5 days ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Seeking treatment at APT Foundation
  • Receiving medications for opioid use disorder (MOUD provided by APT)
  • Have high impact chronic pain (\>= 3 months duration of pain occurring most days which limits life or work activities and/or leads to inability to work)
  • Meet DSM-5 criteria for moderate to severe OUD
  • In the past 2 months, has an opioid-positive urine test or self-reports opioid use
  • Understand English
  • Able to provide informed consent

Exclusion Criteria

  • Have pending surgery or invasive pain management procedure
  • Acutely psychotic, suicidal, or homicidal
  • Psychiatric instability (e.g., recent suicide attempt)
  • Have a contraindication to exercise (e.g. complete heart block)
  • Have a pending or planned relocation or pending incarceration

Arms & Interventions

Treatment as Usual

Treatment as usual for opioid use disorder

SC-POWR

Treatment as usual for opioid use disorder with the addition of CBT with possible stepped care to exercise and stress reduction

Intervention: SC-POWR

Outcomes

Primary Outcomes

Change in pain interference using The Pain, Enjoyment of Life and General Activity (PEG) Scale

Time Frame: Baseline, weekly for 24 weeks, weeks 36 and 48

Pain interference is measured using the PEG scale, a 3-item scale with each item scored from 0-10. Total scores are achieved by averaging the 3 items. Total sore range from 0-10. Higher scores indicate more pain and interference.

Secondary Outcomes

  • Change in alcohol use(Baseline, weekly for 24 weeks, weeks 36 and 48)
  • Change in Anxiety symptoms using General Anxiety Disorder-7 (GAD-7)(Baseline, weekly for 24 weeks, weeks 36 and 48)
  • Change in Depression assessed using Patient Health Questionnaire-9 (PHQ-9)(Baseline, monthly for 24 weeks, weeks 36 and 48)
  • Change in pain intensity assessed using the Brief Pain Inventory (BPI)(Baseline, weekly for 24 weeks, weeks 36 and 48)
  • Change in sleep(Baseline, weekly for 24 weeks, weeks 36 and 48)
  • Change in stress assessed using the Perceived Stress Scale (PSS)(Baseline, monthly for 24 weeks, weeks 36 and 48)
  • Change in composite illicit opioid use(Baseline, weekly for 24 weeks, weeks 36 and 48)

Study Sites (3)

Loading locations...

Similar Trials